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study reports (18 studies), 1 SAS® database pooling data from 16 studies and 1
SAS® database composed of 1 study. While pooling data from these different
sources, several issues had to be faced: 1) the need to harmonize data between
studies; 2) the fact that some variables were not collected in some studies, and 3)
the fact that for 6 studies, part of the data were available only as summarized data.
After taking into account all these issues, an exploitable database was obtained
whose strengths are its large sample size (35 studies comprising 7923 patients), its
range of study settings and designs (phase I to IV across numerous countries) and
the time period encompassed (1990 to 2007). CONCLUSIONS: Pooling data from
various sources raised several problems, not all of them resolvable. However, this
work allowed to obtain an exploitable database with undisputable strengths i.e.
sample size, large range of study settings and design and time period encom-
passed. Once constituted, this database became a valuable tool in evaluating the
safety profile of the virosomal aluminium-free hepatitis A vaccine, and will consti-
tute a valuable database to answer further safety questions in the future.
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OBJECTIVES: Many pharmacoeconomic studies have applied the decision analytic
model or Markov model (collectively termed as static models) to evaluate the cost-
effectiveness of pneumococcal conjugate vaccines without taking herd effect into
account. The objective of the study is to carry out a cost-effectiveness analysis of
13-valent pneumococcal conjugate vaccine PCV13 in Taiwan using a transmission
dynamic model (TDM) to circumvent static models. METHODS: We develop an
age-structured TDM populated with parameters from the Taiwanese National
Health Insurance Research Database (NHIRD), Centers for Disease Control, govern-
ment websites and public available sources to evaluate the clinical and economic
impact of PCV13. Pneumococcal diseases included in the TDM are invasive pneu-
mococcal diseases (IPD), hospitalized pneumonia and acute otitis media (AOM).
One-way deterministic and multivariate probabilistic sensitivity analyses based on
5000 Monte Carlo simulations are performed to explore model uncertainties. Con-
fidence intervals for ICER and cost-effectiveness acceptability curves (CEAC) are
calculated for further inferences. RESULTS: In the base-case analysis, 4-dose
scheduled universal infant PCV13 vaccination is expected to prevent 5,112 cases of
IPD, 535,607 cases of all-cause hospitalized pneumonia, 726,986 cases of AOM, and
420 deaths over a 10-year time horizon. The vaccination program is estimated to
yield an incremental cost-effectiveness ratio (ICER) of US$38,045 and US$18,299
from payer and societal perspectives. One-way sensitivity analyses indicated that
ICER is most sensitive to vaccine price and recovery rate of pneumonia. Ninety-five
percent confidence interval of ICER is US$10,186 to US$34,563 by multivariate prob-
abilistic sensitivity analyses in societal perspective. CONCLUSIONS: With a WHO-
recommended cost-effectiveness threshold of 3 times the gross domestic product
per capita, PCV13 vaccination program would be cost-effective in Taiwan. With the
lack of long-term real data, TDM can be informative to decision makers on evalu-
ating the long term cost-effectiveness of national immunization program.
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OBJECTIVES: Pneumococcal vaccination programmes change the natural course of
infection as the number of susceptible subjects decrease along time. Markovian
and Discrete Event Simulation models enable to capture the whole vaccination
effect as infection rate remains constant. A differential equation dynamic model
based on Anderson and May work was developed to describe how pneumococcal
vaccination modifies the extension of the disease in the susceptible population.
METHODS: Measure of epidemiological effectiveness was the number of conta-
gions avoided by the preventive intervention. No assumptions on mortality and
life-years-gained were considered. The nonlinear ordinary differential equations
system proposed was dS(t)/dt  -*I(t)*S(t)	*I(t)-V(t) dI(t)/dt   *I(t)*S(t)-	*I(t)
where: t  moment in time (months); I(t) and S(t)  number of infective and sus-
ceptible subjects at each time t;   transmission coefficient; 	  natural with-
drawal coefficient. The first order derivatives with respect to t, dI(t)/dt and dS(t)/dt,
indicate the instantaneous variation rates in time of infective and susceptible,
while V(t) indicates the number of vaccinated individuals at each time. Study time
horizon was five years. Spanish 65-years-old cohort annually vaccinated was
318,000 subjects. The parameters to populate the model came from Spanish Min-
istry of Health database (CMBD) and published data. RESULTS: Over a 5-year pe-
riod, the number of avoided contagions derived from the implementation of the
vaccination strategy would be 83,844 with a clear cumulative profile (1,922 on the
1st year; 7,874 on the 2nd; 15,748 on the 3rd; 24,683 on the 4th and 33,617 on the 5th).
CONCLUSIONS: Dynamic models should be used to assess the impact of vaccina-
tion programs for infectious diseases where the infection strength varies along
time. The goodness of fit of this pneumococcal dynamic model was high and cap-
tured health outcomes more easily than alternative modelling methodologies.
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OBJECTIVES: To develop a conceptual framework demonstrating the impact of
Hepatitis C (HCV) and treatment on health-related quality of life (HRQL).
METHODS: 1) PUBMED literature were reviewed. HRQL issues raised by HCV pa-
tients in qualitative studies were compared with those emphasized in quantitative
studies. Numerous issues important to patients were not adequately covered by
commonly used HRQL instruments; 2) An in-depth interview guide was developed
to investigate the issues raised in both study types. HCV patients from France
(n20), Brazil (n20) and Australia (n20) were sampled; and 3) interview data
were examined for recurring issues, which were grouped by concept and theme.
Commonalities and variation within emerging concepts and themes were ex-
plored, iteratively re-examined and refined. RESULTS: The process of analysis fa-
cilitated construction of an HCV-specific HRQL conceptual framework, within
which new and previously identified issues, concepts and themes were organised
into Physical, Mental and Social domains. This framework was compared against
HRQL measures commonly used in HCV research, including the SF-36 and Hepatitis
Quality of Life Questionnaire (HQLQ). HCV-related issues absent or not adequately
represented by these instruments include: (Physical) HIV/HCV co-infection issues,
impact of treatment side effects, mobility change, bodily changes, sexual dysfunc-
tion, and fatigue variability; (Mental) illness uncertainty and unpredictability,
treatment fears, treatment management and adherence, addiction, identity
change, emotional volatility, minor cognitive impairment, concerns for the future,
positive disease impact, and coping; (Social) contagiousness and transmission-
related issues, multidimensional nature of stigma, social isolation and withdrawal,
loss of independence, and reduced participation modes. CONCLUSIONS: Numer-
ous important issues raised by HCV patients are absent or inadequately repre-
sented by commonly used HRQL instruments. The proposed HCV HRQL conceptual
framework encompasses these issues. This forms the foundations for the develop-
ment of a new HCV-specific HRQL instrument. It can also assist health care pro-
viders to educate patients, plan individual interventions, and assess treatment
impact.
Mental Health – Clinical Outcomes Studies
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OBJECTIVES: For patients with major depressive disorder (MDD), adjunctive ther-
apy is often a second treatment step following a partial response to an antidepres-
sant. Although the role of adjunctive treatment is supported in practice guidelines,
there is little information regarding the actual practice of adjunctive therapy, par-
ticularly for patients seen in primary care. The objectives of the study were to
examine the incidence and predictors of adjunctive pharmacotherapy among pa-
tients with MDD treated with selective serotonin reuptake inhibitors (SSRIs) by
primary care physicians (PCPs) in the UK (UK). METHODS: The General Practice
Research Database was used to identify 15,274 patients with MDD who were pre-
scribed first-line treatment with SSRIs from 2006-2008. Treatment trajectories were
identified and classified as adjunctive therapy, drug switches, dose increases, dis-
continuation, and restart of therapy. Incidence and predictors of adjunctive ther-
apy were assessed. Comparisons in healthcare resource utilization were made
between patients receiving adjunctive therapy and patients receiving other treat-
ment strategies. RESULTS: Overall incidence of adjunctive therapy was 3.07/100
person years (95% CI 2.90-3.25). Patients prescribed adjunctive therapy were more
likely to be female (IRR 1.17, p0.02), of higher age (IRRs 1.53-2.41, p0.001), and
had greater depression severity (IRR 1.02, p0.004). Presence of postherpetic neu-
ropathy (IRR 3.06, p0.01), irritable bowel syndrome (IRR 1.33, p0.01), and an
increasing Charlson Comorbidity Index (IRR 1.08, p0.03) were associated with a
higher incidence of adjunctive therapy. MDD-related general practitioner consul-
tations were lower among those prescribed adjunctive therapy compared with
patients receiving other treatment interventions (IRRs 0.79-0.87, p0.001).
CONCLUSIONS: Incidence of adjunctive treatment was relatively low and was as-
sociated with several patient demographics, a higher burden of illness, and less
PCP visits. The incidence of adjunctive therapy suggests that it is infrequently used
in the management of MDD among patients who are partial responders to SSRI
treatment in UK primary care.
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OBJECTIVES: To asses the efficacy of agomelatine, a melatonin MT1/MT2 agonist
and 5-HT2B/5-HT2C antagonist, when compared with placebo and SSRIs.
METHODS:An extensive trials search was conducted on electronic databases, clin-
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ical trials registries, and EMA reports. We extracted data for depression severity
(mean differences or related statistics) on the primary comparisons of 1) agomela-
tine 25 mg/day versus placebo, and 2) agomelatine 25 mg/day versus any SSRI. We
calculated Hedges’ g effect size for each trial and combined them by the inverse
variance method assuming a random effects model. Two meta-analyses were con-
ducted: one with the results of published and unpublished trials and the other only
with results of published trials. RESULTS: Ten trials (5 unpublished) gave data on
the efficacy of agomelatine versus placebo. Overall, the results were homogeneous
(I2  9.2%), and showed agomelatine was better than placebo for reducing the
severity of depression at 8 weeks (g  -0.18; 95% CI  -0.25 to -0.10; p 0.0001).
However when the analysis was restricted to published trials the effect size was
45% overestimated (g  -0.26; 95% CI  -0.36 to-0.15; p  0.0001; I2  3.4%). 7 trials
(4 unpublished) gave data on the comparison of agomelatine versus any SSRI.
There was no difference in efficacy with all trials combined (g 0.01; 95% CI -0.16
to 0.18; p 0.87), but agomelatine significantly outperformed SSRIs in the subset of
published trials (g  -0.17; 95% CI  -0.29 to -0.05; p  0.0052). CONCLUSIONS:
When combining all available data agomelatine presents a small to moderate effi-
cacy as antidepressant with similar effect sizes to those reported for SSRIs. Previ-
ous reports pointing to better results of agomelatine as compared with SSRIs are
the result of selective publication bias.
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OBJECTIVES: This study aimed to describe the functional level of patients treated
with olanzapine long-acting injection (OLZ-LAI) during maintenance treatment of
schizophrenia for up to 24 weeks. A secondary objective was to compare OLZ-LAI
with oral olanzapine on these functional measures. METHODS: We present a sec-
ondary analysis of a multicenter, randomized, double-blind, study comparing the
safety and efficacy of OLZ-LAI (405mg/4weeks, 300mg/2weeks, 150 mgs/2weeks,
active depot groups) with oral olanzapine and OLZ-LAI 45mg/4weeks (very low
dose/pseudo-placebo group) for maintenance treatment of clinically stable pa-
tients with schizophrenia (n1064). Heinrichs and Carpenter’s Quality of Life Scale
(QLS) mean total scores were calculated for each of the three active OLZ-LAI treat-
ment groups and for their pooled group. Patients’ functional status was also clas-
sified - at baseline and endpoint, per QLS - as “good,” “moderate” or “poor” using a
recent data-driven approach to defining levels of functioning in schizophrenia.
RESULTS: Over the 24-week treatment period, the OLZ-LAI-treated patients im-
proved their level of functioning - per QLS total score - from a mean (SD) of 66.4
(18.9) to 72.0(19.1) (p0.001). At baseline, 16.8% of the OLZ-LAI-treated patients
were identified as having a “good” level of functioning, which increased to 27.5%
following up to 24 weeks of therapy (p0.001). There was a decrease both in the
proportion of patients with a “moderate” level of functioning (from 66.8 to 61.8%;
p0.002) and patients with a “poor” level of functioning (from 16.3% to 10.7%;
p0.06). Results were not significantly different between oral olanzapine and the
three OLZ-LAI active dosing groups or the pooled OLZ-LAI treatment group.
CONCLUSIONS: In this 24-week study, clinically stable patients treated with OLZ-
LAI maintained their favorable baseline level of functioning or further improved it
over time. Results did not significantly differ between OLZ-LAI and oral olanzapine.
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OBJECTIVES: Data on attaining and maintaining symptom remission associated
with specific antipsychotic medications are rare and variant. The aim of this study
is to examine remission rates and their variation by antipsychotic medication in
chronic schizophrenia in the National Institute of Mental Health Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) give it has an 18-month duration
and representative antipsychotic medications. METHODS: Symptom remission
was examined using the Remission in Schizophrenia Working Group remission
criteria of attaining and maintaining for 6 months with mild ratings on 8 specific
Positive and Negative Syndrome Scale (PANSS) items. Remission rates were as-
sessed (a) up to 18 months across CATIE’s switching phases (n1332); and (b) in
phase 1 (that involved double-blind randomization to one of five antipsychotic
medications) to compare antipsychotic medication differences in attaining and
maintaining remission among patients not in remission at baseline (n941).
RESULTS: A total of 15.7% of patients were in symptomatic remission at baseline.
Across the switching phases of CATIE only 11% attained and then maintained at
least 6 months of symptomatic remission, and 55.5% (n623) experienced no
symptom remission at any visit. In phase 1, attaining and maintaining remission
for 6 months was highest for the olanzapine (13.3%) medication group followed by
quetiapine (8.9%), ziprasidone (6.6%), perphenazine (6.2%), and risperidone (6.2%)
groups. CONCLUSIONS: As currently defined, remission appears to be a very diffi-
cult therapeutic target to attain and maintain in chronic schizophrenia and may
differ by antipsychotic medication. Pragmatically, remission gradients may be ef-
fectively studied by applying modified duration and symptom criteria.
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OBJECTIVES:Despite marked heterogeneity among patients with schizophrenia in
their level of functioning, little is known what “good” “moderate” or “poor” levels of
functioning look like on various functional measures. This study used an empirical
approach to identify and then validate these functional definitions.METHODS:We
used baseline data of a multicenter, effectiveness study comparing antipsychotics
in the treatment of outpatients with schizophrenia (n524; NCT00320489), as this
study included several functional measures. A cluster analysis used the Heinrich’s
Carpenter Quality of Life Scale (QLS), the 12-item Short Form Health Survey (SF-12)
mental composite score, and a previously studied productivity measure, to classify
patients into functional groups. A three cluster solution was chosen to maximize
simplicity, explanatory power and separation among the groups. Clusters were
validated using two other functional measures and two previously published def-
initions of functional levels: an empirical definition that incorporated functioning
and symptom severity, and another, using theoretically-driven definitions. Classi-
fication and regression tree (CART) analysis was used to establish the criteria for
classifying functioning as “good” “moderate” or “poor” with the QLS. RESULTS: The
three clusters consistently differentiated patients on the QLS, SF-12 and produc-
tivity measures, reflecting “good” “moderate” and “poor” functional levels. The
clusters similarly differed on other functional measures (the Schizophrenia Out-
comes Functioning Interview [SOFI] and the Euro-QOL-5D scale), and were concor-
dant with two previously published functional classifications. The CART analysis
identified “good” functioning as QLS total score 84.5, whereas “moderate” and
“poor” functioning were separated by a cut-off score of 15.5 on the QLS intrapsychic
foundation domain. Sensitivity ranged from 86% to 93% and specificity from 89% to
99%. CONCLUSIONS: The substantial heterogeneity among schizophrenia patients
in their level of functioning can be reliably classified in an empirical manner, using
specific cut-off scores on commonly used functional measures. Findings have util-
ity for schizophrenia research.
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OBJECTIVES: Treatment continuity plays a major role in achieving favorable out-
comes in patients suffering from schizophrenia. Long-acting injectable risperidone
(RLAI) has shown its beneficial effects compared to oral antipsychotics (oAP) in
randomized controlled trials, but observational data reflecting routine clinical
practice are sparse. Objective is to evaluate the clinical effectiveness of RLAI com-
pared to oAP in clinical practice. METHODS: A total of 746 patients with schizo-
phrenia newly initiated from oral antipsychotic treatment to either an atypical oAP
(n268) or RLAI (n478) were enrolled in this prospective, longitudinal 24-month
open-label observational study. Primary efficacy measure was time to discontinu-
ation of medication using Kaplan-Meier and multivariate Cox proportional hazards
regression, adjusting for patient demographics, disease severity and treatment
history. RESULTS: At baseline, patients treated with RLAI were more likely to be
male, non-compliant, substance abuser, and had significantly higher levels of psy-
chotic symptoms and disease severity, poorer psychosocial functioning (GAF, days
unable to work), and poorer cognitive function, compared to patients treated with
oral antipsychotics. 107 patients were identified as having a history of poor adher-
ence (RLAI: n84; oral: n23) with previous antipsychotic treatment. Time to treat-
ment discontinuation was numerically but not significantly longer for patients
treated with RLAI compared to patients treated with atypical oAP. Among the
subset of patients with history of poor adherence this difference was significant
(unadjusted hazard ratio0.42, p.014; adjusted hazard ratio0,35; p0,0098).
Symptom improvement was significantly better for patients on RLAI as compared
to oAP on the Positive and Negative Syndrome Scale (PANSS) total score (p.029),
positive (p.004) and negative (p.023) subscores, respectively. CONCLUSIONS: In
routine clinical practice, RLAI appears to be used more frequently in patients with
more severe schizophrenia, substance abuse and poor adherence. The benefits of
RLAI treatment compared to oAP seem to be most pronounced in a subset of pa-
tients with poor adherence.
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ASENAPINE VERSUS OTHER ANTIPSYCHOTICS IN BIPOLAR I DISORDER:
INDIRECT COMPARISONS AT TWELVE WEEKS
Sapin C, Corson H, Beillat M, Hansen K
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OBJECTIVES: Asenapine is a novel antipsychotic indicated for the treatment of
moderate to severe manic episodes associated with bipolar I disorder. The clinical
programme included one 12-week trial versus olanzapine in monotherapy and one
12-week adjunct therapy trial versus placebo. While no head-to-head data were
available to compare asenapine with all atypical antipsychotics, the objective of
this project was to provide comparative efficacy data of asenapine versus olanzap-
ine, quetiapine and aripiprazole in both monotherapy and adjunct therapy using
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